Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/8/2007

Submits Iloperidone New Drug Application (NDA); Begins Phase III Chronic Insomnia Study for VEC-162; Reports Results in VSF-173 Phase II Proof of

Concept Trial; Updates Full Year 2007 Financial Guidance

ROCKVILLE, Md., Nov. 8 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2007.

Vanda reported research and development (R&D) expenses in the third quarter of 2007 of $13.9 million, compared to second quarter of 2007 R&D expenses of $10.2 million and third quarter of 2006 R&D expenses of $9.5 million. The increase in R&D expenses in the third quarter of 2007 relative to the second quarter of 2007 is primarily attributable to a $5.0 million milestone charge resulting from the submission of the iloperidone NDA, which was partially offset by lower clinical trial costs associated with the completion of the long-term open label portion of the Phase III trial for iloperidone. The increase in R&D expenses in the third quarter of 2007 relative to the third quarter of 2006 was also primarily attributable to the $5.0 million NDA milestone charge, which was partially offset by lower clinical trial expenses for the company's iloperidone and VEC-162 Phase III trials that were primarily completed in 2006. Total expenses for the third quarter of 2007 were $23.5 million, compared to $17.6 million in the second quarter of 2007 and $12.8 million in the third quarter of 2006.

Net loss applicable to common stockholders was $21.9 million for the third
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an emphasis ... announces that Company management will participate in the upcoming ... March 8-11, 2015 at the Ritz Carlton Laguna Niguel ... Jennifer Simpson , PhD, MSN, CRNP, Delcath,s interim President ...
(Date:3/2/2015)... NORTH HOLLYWOOD, Calif. , March 2, 2015 ... improving the quality of life of myeloma patients ... once again declared the month of March to ... IMF first established March as Myeloma Awareness Month ... information about the disease through local community events, ...
(Date:3/2/2015)... DUBLIN , Mar. 02, 2015 Research ... announced the addition of the "Lopinavir - ... , Imagine having your own ... of a button. Used by the ... over 10 years, these searches are the benchmark ...
Breaking Medicine Technology:Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Global Comprehensive Lopinavir Patent Search Online Portal 2015 2
... 4, 2011 WebMD Health Corp. (Nasdaq: WBMD ... deliver a presentation at the UBS 21st Annual Global Healthcare ... ET. Investors, analysts and the general public are ... presentation over the Internet.  The broadcast can be accessed at ...
... K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a ... informed by Hologic, Inc. that the U.S. Food and ... injection).  Makena, commonly referred to as "17P," is the ... risk of preterm birth in women with a singleton ...
Cached Medicine Technology:FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 3FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 4FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 5FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 6FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 7FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 8FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 9FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 10FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 11FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 12
(Date:3/2/2015)... Minneapolis, Minnesota (PRWEB) March 02, 2015 ... a new strategic relationship with First Protective Insurance ... new initiative will allow First Protective affiliated advisors ... and implementation support that Secura Consultants delivers. ... is a national leader in the design and ...
(Date:3/1/2015)... Minneapolis, MN (PRWEB) March 02, 2015 ... leader in the ancillary benefits market, announced the ... product offering. PrimeStar Individual Vision Insurance launched today, ... Choice Vision plan will utilize the VSP® Vision ... providers in the private practice space. The PrimeStar ...
(Date:3/1/2015)... 01, 2015 Women’s Excellence is pleased ... terms on their website. There are over 75 terms ... time. , “This gives our patients a better understanding ... terminology that they may not understand. With this resource, our ... mobile optimized) and find terms and phrases that they may not ...
(Date:3/1/2015)... Los Angeles, CA (PRWEB) March 01, 2015 ... will now be possible when using the Quotes Pros ... now available including United auto insurance rates that are ... , Access to the updated agencies and prices available ... a consumer's zip code online. Every system user will ...
(Date:3/1/2015)... Raleigh, NC (PRWEB) March 01, 2015 ... the reason that so many sheet metal workers contract ... of this new report on its website. Click ... the Center for Construction Research and Training monitored 17,345 ... that a disproportionate number of them died of ...
Breaking Medicine News(10 mins):Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2
... TUCSON, Ariz., July 7 The Providence Service Corporation (Nasdaq: ... in California as part of the state,s attempt to close ... we have stated previously, given that our programs in California ... Act (Proposition 63 of 2004), we do not expect to ...
... been linked to fatal overdoses , TUESDAY, July ... of fatal overdoses led U.S. health officials Tuesday ... of using pain medications containing propoxyphene, including Darvon ... of propoxyphene-containing products by adding boxed warnings that ...
... way to eat healthier without sacrificing taste just got easier. ... lovers are invited to discover the great taste of Barilla ... tries and is not completely satisfied with Barilla Whole Grain ... pasta. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090707/NY41858-a ...
... Crawford Canada,s Bill Johnstone has been named senior vice ... ; CRDB) Global Technical Services (GTS) for the Americas, ... and grow this market-leading service, the Company announced today. ... Crawford worldwide in the high-end, complex loss adjusting market. ...
... KNOXVILLE, Tenn., July 7 TeamHealth Medical Call ... its third Health Care Call Center certificate of ... accrediting organization that establishes quality standards for the ... provides comprehensive medical call center services including nurse ...
... King Pharmaceuticals, Inc. (NYSE: KG ) today announced ... Drug Application (NDA). The Company is not required by ... trials in order to provide additional safety or efficacy data ... of the resubmission plan, and in order to strengthen the ...
Cached Medicine News:Health News:Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 2Health News:FDA Mandates Tougher Warnings for Pain Pills 2Health News:Barilla(R) and Celebrity Fitness Coach Bob Greene Challenge Americans to Discover the Great Taste of Whole Grain 2Health News:Barilla(R) and Celebrity Fitness Coach Bob Greene Challenge Americans to Discover the Great Taste of Whole Grain 3Health News:Bill Johnstone Named Senior Vice President of Crawford's Global Technical Services for the Americas 2Health News:TeamHealth Medical Call Center Awarded Third Consecutive URAC Health Call Center Accreditation 2Health News:King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan 2
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
Medicine Products: